
Healthcare workers prepare doses of the Moderna coronavirus disease (COVID-19) vaccine before administering them to staffers of Japan’s supermarket group Aeon at the company’s shopping mall in Chiba, Japan, on June 21, 2021.
11:50 JST, June 3, 2022
A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc’s COVID-19 vaccine.
The study of 5,893 participants between May and November last year showed that 22.4% of women developed delayed skin reactions after the first shot, compared to 5.1% of men.
The symptoms were mild and not considered a contraindication of the mRNA-based vaccine, according to the June 1 report in JAMA Dermatology.
Delayed skin reactions, happening on or after six days from the shot, have been also reported as a rare adverse event in the United States and Europe, according to the authors from Tokyo’s Self-Defense Forces Central Hospital.
But the incidences appear to be higher in Japan, they wrote, perhaps because of a higher awareness of such symptoms in the country. The greater likelihood among women may be due to differences in weight as well as hormonal and environmental factors, they said.
Moderna representatives in the United States and Japan did not immediately respond to a request for comment.
Top Articles in Society
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
15 Measles Patients Confirmed in Tokyo in Past 6 Days; 1 May Have Come into Contact with Many in Shibuya
-
Bus Carrying 40 Passengers Catches Fire on Chuo Expressway; All Evacuate Safely
-
Ibaraki Pref.’s 1st Foreign Bus Driver Hired in Tsukuba
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

